A Study to Assess Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia


About this study

This study is designed to learn more about the use of a new imaging agent AV-1451 which shows strong binding to abmormal tau in the brain, to see if it will allow positron emission tomography (PET) scanning of tau in the brains of patients with Primary Progressive Aphasia.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Must be over the age of 18.
  • Must speak English as primary language.
  • Must have an informant who can provide independent evaluation of functioning.
  • Must present with a chief complaint of progressive impairment of speech or language.
  • Must fulfill diagnostic criteria for Primary Progressive Aphasia.

Exclusion Criteria:

  • Any subject who is mute or whose speech is unintelligible will be excluded.
  • All subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes, and subjects meeting criteria for another neurodegenerative disease, such as amnestic Alzheimer's type dementia, dementia with Lewy bodies, behavioral variant frontotemporal dementia, progressive supranuclear palsy, and corticobasal syndrome.
  • Subjects who meet criteria for PPA and have mild behavioral changes, eye movement abnormalities or mild limb apraxia but who do not meet diagnostic criteria for behavioral variant frontotemporal dementia, progressive supranuclear palsy, or corticobasal syndrome respectively.
  • All pregnant, post-partum and breast-feeding women.
  • Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, etc.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g., structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g., chemotherapy).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Keith Josephs, M.D.

Open for enrollment

Contact information:

Sarah Boland CCRP



More information


Publications are currently not available